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Background
The options for secondary prevention of cryptogenic embolism in patients with pat-
ent foramen ovale are administration of antithrombotic medications or percutaneous 
closure of the patent foramen ovale. We investigated whether closure is superior to 
medical therapy.
Methods
We performed a multicenter, superiority trial in 29 centers in Europe, Canada, Brazil, 
and Australia in which the assessors of end points were unaware of the study-group 
assignments. Patients with a patent foramen ovale and is che mic stroke, transient 
is che mic attack (TIA), or a peripheral thromboembolic event were randomly as-
signed to undergo closure of the patent foramen ovale with the Amplatzer PFO 
Occluder or to receive medical therapy. The primary end point was a composite of 
death, nonfatal stroke, TIA, or peripheral embolism. Analysis was performed on data 
for the intention-to-treat population.
Results
The mean duration of follow-up was 4.1 years in the closure group and 4.0 years in 
the medical-therapy group. The primary end point occurred in 7 of the 204 patients 
(3.4%) in the closure group and in 11 of the 210 patients (5.2%) in the medical-
therapy group (hazard ratio for closure vs. medical therapy, 0.63; 95% confidence 
interval [CI], 0.24 to 1.62; P = 0.34). Nonfatal stroke occurred in 1 patient (0.5%) in the 
closure group and 5 patients (2.4%) in the medical-therapy group (hazard ratio, 0.20; 
95% CI, 0.02 to 1.72; P = 0.14), and TIA occurred in 5 patients (2.5%) and 7 patients 
(3.3%), respectively (hazard ratio, 0.71; 95% CI, 0.23 to 2.24; P = 0.56).
Conclusions
Closure of a patent foramen ovale for secondary prevention of cryptogenic embolism 
did not result in a significant reduction in the risk of recurrent embolic events or 
death as compared with medical therapy. (Funded by St. Jude Medical; ClinicalTrials 
.gov number, NCT00166257.)
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Paradoxical embolism by means of a patent foramen ovale has been blamed as a cause of stroke and other systemic is che-
mic events since the 19th century.1 The actual 
passage of a venous clot through a patent foramen 
ovale has been documented in a few cases and 
resulted in systemic embolic events such as is-
che mic stroke, transient is che mic attack (TIA),2-6 
or myocardial infarction.7 Catheter-based closure 
of patent foramen ovale was introduced in 1992.8
Observational long-term data suggest that 
closure of patent foramen ovale in patients with 
a history of is che mic stroke may reduce the risk 
of recurrent stroke as compared with medical 
therapy alone.9,10 However, meta-analyses11-16 
suggest that adverse effects of catheter-based 
closure of patent foramen ovale may result in a 
clinical course inferior to that after medical treat-
ment. A science advisory from the American Heart 
Association and the American Stroke Association 
recommended restricting the closure of patent 
foramen ovale to randomized trials.17 We initi-
ated the Clinical Trial Comparing Percutaneous 
Closure of Patent Foramen Ovale (PFO) Using the 
Amplatzer PFO Occluder with Medical Treatment 
in Patients with Cryptogenic Embolism (PC Trial) 
14 years ago to determine whether the closure of 
patent foramen ovale is superior to medical ther-
apy in preventing recurrence of embolic events.18
Me thods
Study Design and Oversight
The PC Trial was conducted at 29 sites in Europe, 
Canada, Brazil, and Australia. The trial design has 
been described previously.18 The academic mem-
bers of the steering committee (see the Supple-
mentary Appendix, available with the full text of 
this article at NEJM.org) designed the study with-
out involvement of the funder, St. Jude Medical. An 
independent data and safety monitoring board 
(see the Supplementary Appendix) met periodi-
cally for oversight of the trial. No formal stop-
ping rules were specified. The funder was not 
involved in the conduct of the trial, the writing of 
the manuscript, or the decision to submit the 
manuscript for publication, but it did provide or-
ganizational support for the adjudication of clin-
ical events and the meetings of the data and 
safety monitoring board.
The members of the steering committee, the 
trial statistician, and the senior author had full 
access to all the data in the study, wrote the 
manuscript, and had final responsibility for the 
decision to submit the manuscript for publica-
tion. These same authors vouch for the accuracy 
of the data and analyses and for the fidelity of 
the study to the protocol, available at NEJM.org. 
The study was conducted in accordance with the 
Declaration of Helsinki and was approved by the 
institutional ethics committee at each site. All 
patients provided written informed consent.
Study Patients and Randomization
Patients less than 60 years of age with a patent 
foramen ovale documented on transesophageal 
echocardiography and no other identifiable cause 
of stroke or peripheral thromboembolism were 
eligible for the study if they presented with clini-
cally and neuroradiologically verified is che mic 
stroke, a TIA with a neuroradiologically verified 
cerebral is che mic lesion, or a clinically and radio-
logically verified extracranial peripheral thrombo-
embolic event.
Patients underwent central randomization by 
means of a Web-based system either to undergo 
percutaneous, catheter-based closure of the pat-
ent foramen ovale (closure group) with the use of 
the Amplatzer PFO Occluder (St. Jude Medical) or 
to receive medical therapy (medical-therapy group). 
See the Supplementary Appendix for details re-
garding eligibility criteria, echocardiographic char-
acterization of patent foramen ovale, and random-
ization. Patients were followed up in the hospital 
and in office visits at 6 months and annually for 
up to 5 years (see the Supplementary Appendix).
Study Procedures and Antithrombotic 
Treatments
Patients in the closure group were generally ad-
mitted on the day of the procedure and discharged 
the same day or the following day. The closure 
procedure was typically performed with the use 
of local anesthesia, and device implantation was 
guided by means of fluoroscopy with or without 
transesophageal or intracardiac echocardiography. 
Prophylactic antibiotic therapy was recommended 
during the periprocedural period, and prophylaxis 
against endocarditis was recommended for 2 to 
6 months after closure of the patent foramen ovale.
Recommended antithrombotic treatment in 
the closure group included acetylsalicylic acid at 
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a dose of 100 to 325 mg per day for at least 5 to 
6 months, as well as ticlopidine at a dose of 
250 to 500 mg per day or clopidogrel at a dose 
of 75 to 150 mg per day for 1 to 6 months. For 
patients with intolerance to acetylsalicylic acid, 
ticlopidine or clopidogrel alone was recom-
mended.
In the medical-therapy group, antithrombotic 
treatment was left to the discretion of the treating 
physician and could have included antiplatelet 
therapy or oral anticoagulation, provided that pa-
tients received at least one antithrombotic drug.
Study End Points
The prespecified primary end point was a com-
posite of death, nonfatal stroke, TIA, or periph-
eral embolism. Secondary end points were the 
individual components of the primary end point 
as well as cardiovascular death, new arrhythmias 
(particularly new-onset atrial fibrillation), myo-
cardial infarction, hospitalization related to the 
patent foramen ovale or its treatment, device 
problems, and bleeding (see the Supplementary 
Appendix for outcome definitions).18 A clinical-
events committee whose members were unaware 
of study-group assignments independently adju-
dicated all potential events.
Statistical Analysis
We calculated that a sample size of 205 patients 
per group would yield a power of 80% to detect a 
reduction in the rate of the primary composite 
end point from 3% to 1% per year19-21 over a 
mean follow-up period of 4.5 years and at an alpha 
level of 0.0492 (allowing for one interim analysis). 
No interim analysis was actually performed; there-
fore, we used the conventional alpha level of 0.05.
Cox proportional-hazard models were used to 
calculate hazard ratios, 95% confidence intervals, 
and corresponding P values. The primary analysis 
was of data from the intention-to-treat population. 
In a per-protocol analysis, we restricted the analy-
sis to data from patients in the closure group in 
whom implantation of a device was attempted and 
patients in the medical-therapy group who re-
ceived treatment as assigned at the time of ran-
domization; if patients in the medical-therapy 
group crossed over to the closure group, the data 
were censored at the time of crossover. (See the 
Supplementary Appendix for details regarding 
the statistical methods.)
R esult s
Study Patients
Between February 24, 2000, and February 19, 2009, 
a total of 414 patients were enrolled, of whom 
204 were randomly assigned to the closure group 
and 210 to the medical-therapy group (Fig. S1 in 
the Supplementary Appendix). Baseline charac-
teristics were similar in the two groups (Table 1). 
The mean ages in the closure group and the 
medical-therapy group were 44.3 years and 44.6 
years, respectively, and the mean body-mass in-
dexes (the weight in kilograms divided by the 
square of the height in meters) were 26.6 and 
26.3, respectively.
Data on transesophageal echocardiography 
were available for 185 patients in the closure 
group and 184 patients in the medical-therapy 
group. The results showed a large right-to-left 
shunt in 43 patients (23.2%) and 37 patients 
(20.1%), respectively. The patients in our study 
were younger (P = 0.006), had a lower rate of dia-
betes (P<0.001), and were less likely to be men 
(P = 0.08), as compared with 39 cohorts of pa-
tients in a meta-analysis who underwent closure 
of patent foramen ovale in routine clinical set-
tings14 (Fig. S2 in the Supplementary Appendix).
Study Treatments and Follow-up
Among the 204 patients in the closure group, 
device implantation was attempted in 196 and 
was completed in 191 (Fig. S1 in the Supplemen-
tary Appendix). In 2 patients who underwent de-
vice implantation there was access-site bleeding, 
and in another patient there was transient peri-
procedural atrial fibrillation of less than 24 
hours’ duration. All three events were classified 
as minor procedural complications. Therefore, 
implantation was deemed to be successful in 188 
of the 196 patients (95.9%) in whom it was at-
tempted.
At 6 months, 148 patients in the closure group 
underwent transesophageal echocardiography. 
Of these patients, the device was correctly posi-
tioned in 145 (133 with no shunt, 9 with minimal 
shunt, 1 with moderate shunt, and 2 with severe 
shunt). Effective closure was defined as closure 
with no or minimal shunting and therefore was 
achieved in 142 of the 148 patients (95.9%).
Among the 210 patients in the medical-therapy 
group, 200 received the intervention as assigned, 
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4 had no documented antiplatelet or anticoagu-
lant treatment at discharge, and 6 crossed over 
and underwent closure of patent foramen ovale 
during the first month after randomization. 
Subsequently, 22 more patients in the medical-
therapy group crossed over to the closure group. 
The median time to closure of patent foramen 
ovale in the 28 patients who crossed over from 
the medical-therapy group was 8.8 months (inter-
quartile range, 1.2 to 26.4) (Fig. S3 in the Supple-
mentary Appendix). Reasons for crossover included 
patient preference (in 19 patients), stroke (in 4 pa-
tients), TIA (in 2 patients), and physician prefer-
ence (in 3 patients).
Table S1 in the Supplementary Appendix shows 
the frequency of the use of antithrombotic medi-
cation in the two study groups. From 12 months 
onward, antithrombotic treatment was signifi-
cantly less frequent in the closure group than in 
the medical-therapy group (P<0.001 for each year). 
Use of oral anticoagulation was significantly less 
common in the closure group at all time points, 
including at discharge and at 6 months (P<0.001 
for all comparisons).
The mean duration of follow-up was 4.1 years 
in the closure group and 4.0 years in the medical-
therapy group, with 845.1 and 835.0 patient-years 
of accumulated follow-up time, respectively. Sev-
en patients in the closure group and 11 in the 
medical-therapy group withdrew from the study; 
24 and 31 others, respectively, were lost to follow-
up (Fig. S1 in the Supplementary Appendix). 
Patients with incomplete follow-up were less 
frequently obese (P = 0.02) and had a lower rate 
of hypercholesterolemia (P = 0.001) than those 
with complete follow-up (Table S2 in the Supple-
mentary Appendix).
Efficacy Outcomes
Potential primary end points occurred in 9 pa-
tients in the closure group and 18 patients in the 
medical-therapy group. After independent adju-
dication, the primary end point was confirmed 
to have occurred in 7 patients (3.4%) in the clo-
sure group and 11 patients (5.2%) in the medical-
therapy group (hazard ratio for closure vs. medical 
therapy, 0.63; 95% confidence interval [CI], 0.24 to 
1.62; P = 0.34) (Table 2). Figure 1 presents the 
corresponding Kaplan–Meier curves for the pri-
mary composite end point. Results of the per-
protocol analysis of the primary composite end 
point were similar to the intention-to-treat analy-
sis, with a hazard ratio of 0.70 (95% CI, 0.27 to 
1.85; P = 0.48).
In an analysis of the individual components 
of the primary end point, stroke occurred in one 
patient (0.5%) in the closure group and five pa-
tients (2.4%) in the medical-therapy group (haz-
ard ratio, 0.20; 95% CI, 0.02 to 1.72; P = 0.14), 
with all strokes being confirmed on neuroimag-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
PFO Closure  
(N = 204)
Medical Therapy  
(N = 210)
Age — yr 44.3±10.2 44.6±10.1
Male sex — no. (%) 92 (45.1) 114 (54.3)
Body-mass index† 26.6±5.6 26.3±4.8
Family history of cerebrovascular event —  
no. (%)
53 (26.0) 40 (19.0)
Current smoker — no. (%) 52 (25.5) 47 (22.4)
Arterial hypertension — no. (%) 49 (24.0) 58 (27.6)
Diabetes mellitus — no. (%) 5 (2.5) 6 (2.9)
Hypercholesterolemia — no. (%) 50 (24.5) 62 (29.5)
Valvular heart disease — no. (%) 8 (3.9) 5 (2.4)
Peripheral vascular disease — no. (%) 3 (1.5) 2 (1.0)
Coronary artery disease — no. (%) 4 (2.0) 4 (1.9)
History of myocardial infarction — no. (%) 3 (1.5) 1 (0.5)
Migraine — no. (%) 47 (23.0) 38 (18.1)
Cerebrovascular index event — no. (%)
Peripheral embolism 6 (2.9) 5 (2.4)
Transient ischemic attack 33 (16.2) 42 (20.0)
Stroke 165 (80.9) 163 (77.6)
>1 Previous cerebrovascular event — no. (%) 76 (37.3) 79 (37.6)
Time from index event to randomization — mo
Median 4.3 4.5
Interquartile range 1.1–8.2 1.3–8.9
Atrial septal aneurysm — no. (%) 47 (23.0) 51 (24.3)
Interatrial right-to-left shunt — no./ 
total no. (%)‡
Small 55/185 (29.7) 72/184 (39.1)
Medium 87/185 (47.0) 75/184 (40.8)
Large 43/185 (23.2) 37/184 (20.1)
* Plus–minus values are means ±SD. There were no significant differences (P<0.05) 
between the two groups for any of the baseline characteristics. PFO denotes 
patent foramen ovale.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ Baseline transesophageal echocardiography was performed for 185 patients in 
the closure group and 184 patients in the medical-therapy group, providing 
information on grading of right-to-left shunts.
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ing studies (Table 2, and Fig. S4, S5, and S6 in 
the Supplementary Appendix). TIAs occurred in 
five patients (2.5%) and seven patients (3.3%), 
respectively (hazard ratio, 0.71; 95% CI, 0.23 to 
2.24; P = 0.56). There were no peripheral embolic 
events.
In an exploratory analysis based on a contem-
porary stroke definition,22 as used in the Random-
ized Evaluation of Recurrent Stroke Comparing 
PFO Closure to Established Current Standard of 
Care Treatment (RESPECT) trial,23 one patient in 
the closure group and seven patients in the 
medical-therapy group had a stroke (hazard ra-
tio, 0.14; 95% CI, 0.02 to 1.17; P = 0.07). Two pa-
tients in the closure group (1.0%) versus no pa-
tients in the medical-therapy group died (hazard 
ratio, 5.20; 95% CI, 0.25 to 107.61; P = 0.24). One 
patient died of respiratory failure caused by chron-
ic obstructive pulmonary disease, and the other 
from a glioma.
Figure 2 presents results from subgroup analy-
ses. There were statistical trends toward a sub-
group interaction for age and the presence or 
absence of an atrial septal aneurysm, but there 
were no formally significant differences between 
subgroups (P = 0.10 and P = 0.09 for interaction, 
respectively).
Adverse Events
A total of 113 adverse events were reported in 
71 patients (34.8%) in the closure group and 
120 events in 62 patients (29.5%) in the medical-
therapy group (Table 3). Of these, 60 events in 
43 patients (21.1%) in the closure group and 
Table 2. Clinical Outcomes.*
Outcome
PFO Closure 
(N = 204)
Medical Therapy 
(N = 210)
Hazard Ratio or Relative 
Risk (95% CI)† P Value
no. of patients (%)
Primary composite outcome of death, stroke, 
TIA, or peripheral embolism
7 (3.4) 11 (5.2) 0.63 (0.24–1.62) 0.34
Death‡ 2 (1.0) 0 5.20 (0.25–107.61) 0.24
Cardiovascular 0 0 NA
Noncardiovascular 2 (1.0) 0 5.20 (0.25–107.61) 0.24
Thromboembolic event
Stroke§ 1 (0.5) 5 (2.4) 0.20 (0.02–1.72) 0.14
TIA 5 (2.5) 7 (3.3) 0.71 (0.23–2.24) 0.56
Peripheral embolism 0 0 NA
Secondary composite outcome of stroke, TIA, 
or peripheral embolism
5 (2.5) 11 (5.2) 0.45 (0.16–1.29) 0.14
* NA denotes not applicable, PFO patent foramen ovale, and TIA transient ischemic attack.
† Hazard ratios were calculated by means of the Cox proportional-hazards model. For the comparison of deaths (for which 
one group had no events), the relative risk was calculated instead of the hazard ratio with the use of continuity correction, 
and the corresponding P value was obtained by means of a two-sided Fisher’s exact test.
‡ One patient died of respiratory failure because of chronic obstructive pulmonary disease; the other died from a glioma.
§ All listed strokes were major strokes.
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Figure 1. Kaplan–Meier Cumulative Estimates of the Rate of the Primary 
End Point.
PFO denotes patent foramen ovale.
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56 events in 37 patients (17.6%) in the medical-
therapy group were adjudicated as serious.
New-onset atrial fibrillation was observed in 
six patients (2.9%) in the closure group and in 
two patients (1.0%) in the medical-therapy group 
(hazard ratio, 3.15; 95% CI, 0.64 to 15.6; 
P = 0.16); none of these patients subsequently had 
a potential or confirmed primary-end-point event. 
Of the six affected patients in the closure group, 
two had transient atrial fibrillation, two had 
pharmacologic and one had electrical conversion 
to sinus rhythm, and one had sustained atrial 
fibrillation. Of the two affected patients in the 
medical-therapy group, one had pharmacologic 
conversion to sinus rhythm, and one had sus-
tained atrial fibrillation.
There was no evidence of device-associated 
thrombi in any patient. Myocardial infarction oc-
curred in 2 patients (1.0%) in the closure group 
and 1 patient (0.5%) in the medical-therapy 
group (hazard ratio, 2.04; 95% CI, 0.19 to 22.5; 
P = 0.62); hospital admission related to patent fo-
ramen ovale occurred in 13 patients (6.4%) and 
13 patients (6.2%), respectively (hazard ratio, 1.02; 
95% CI, 0.48 to 2.21; P = 0.95). Bleeding occurred 
in 8 patients (3.9%) undergoing closure and 12 
patients (5.7%) receiving medical therapy (hazard 
ratio, 0.66; 95% CI, 0.27 to 1.62; P = 0.40).
Discussion
In this trial, closure of patent foramen ovale with 
the Amplatzer PFO Occluder for secondary pre-
vention of cryptogenic embolism did not result in 
a significant reduction in the risk of embolic 
events or death, as compared with medical ther-
apy alone. There were fewer strokes in the clo-
sure group, but overall, few patients had a stroke 
and the difference was not significant. Our trial 
was designed to detect a reduction of 66% in the 
risk of embolic events or death, from 3% per year 
in the medical-therapy group to 1% per year in 
the closure group. However, at a mean follow-up 
of 4 years, we found an event rate of 5.2% in the 
medical-therapy group, which was less than half 
of the anticipated 12%. The power of our trial to 
detect the planned reduction of 66% in relative 
risk was therefore less than 40%. Thus, there is a 
risk of a type II error in our trial — that is, a 
clinically relevant benefit of the closure of patent 
foramen ovale might exist but we were unable to 
detect it.
When we designed our trial in 1999, only a 
few relevant studies had been performed.14 We 
based our assumptions on observational studies 
using data from a population-based stroke reg-
istry, which reported a rate of recurrent crypto-
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Figure 2. Subgroup Analyses of the Primary End Point.
Hazard ratios were calculated with the use of a Cox proportional-hazards model. 
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genic embolism–related events of 3.8% per year 
among patients receiving medical treatment19 
but 0% among patients who had undergone sur-
gical closure of patent foramen ovale.20,21 The 
patients in our study appeared to have been at 
lower risk for cardiovascular events than the co-
horts of patients who underwent closure of pat-
ent foramen ovale in routine clinical settings14 
(Fig. S2 in the Supplementary Appendix), a fac-
tor that may have contributed to the consider-
ably lower-than-expected event rate in our study.
Our trial has several limitations. First, our 
primary composite end point may be considered 
problematic. Overall death accounts for all po-
tential benefits and harms of the experimental 
intervention but is not specific to the studied 
condition. TIA is a less clear-cut end point than 
stroke. Including TIA as a component resulted in 
an increased event rate but also may have re-
sulted in a dilution of effects, as suggested by 
the difference in the estimated hazard ratios for 
stroke (0.20) and TIA (0.71). Second, we had dif-
ficulty recruiting patients, which led to an un-
usually long recruitment period and a selected 
patient population, which may in turn limit the 
generalizability of our findings.24 Third, patient 
retention was lower than expected, which might 
have resulted in attrition bias that could distort 
the results in either direction.24 Fourth, the 
clinical-events committee discounted potential 
primary-end-point events more often in the 
medical-therapy group than in the closure group. 
Even though the numbers of discounted events 
were small, this difference could constitute indi-
rect evidence of selective reporting of potential 
events, owing to the open nature of the trial: 
mild or transient events in patients in the clo-
sure group may have been less likely to be re-
ported than events in the medical-therapy group 
if investigators or patients were confident that 
successful closure of patent foramen ovale re-
duces the risk of another event.
Two other trials have compared closure of pat-
ent foramen ovale with medical therapy for sec-
ondary prevention of cryptogenic embolism. The 
CLOSURE I (Evaluation of the STARFlex Septal 
Closure System in Patients with a Stroke and/or 
Transient Is che mic Attack due to Presumed Para-
doxical Embolism through a Patent Foramen 
Ovale) study, the results of which were published 
in March 2012,25 had a similar primary compos-
ite end point to the one in our study: stroke or 
Table 3. Adverse Events.*
Adverse Event
PFO Closure 
(N = 204)
Medical Therapy  
(N = 210) P Value
no. of patients (%)
Procedural complication† 3 (1.5) 0 0.12
PFO-related hospital admission‡ 13 (6.4) 13 (6.2) 0.95
Myocardial infarction‡ 2 (1.0) 1 (0.5) 0.62
Atrial fibrillation§ 6 (2.9) 2 (1.0) 0.17
Serious 2 (1.0) 2 (1.0) 1.00
Minor 4 (2.0) 0 0.058
Bleeding 8 (3.9) 12 (5.7) 0.40
Serious 1 (0.5) 3 (1.4) 0.62
Minor 7 (3.4) 9 (4.3) 0.65
Any adverse event 71 (34.8) 62 (29.5) 0.25
Serious 43 (21.1) 37 (17.6) 0.37
Minor 40 (19.6) 42 (20.0) 0.92
Other adverse event, occurring  
in ≥3 patients
Headache 3 (1.5) 1 (0.5) 0.37
Migraine 5 (2.5) 5 (2.4) 1.00
Syncope 2 (1.0) 1 (0.5) 0.62
Dizziness 1 (0.5) 4 (1.9) 0.37
Paresthesia 0 3 (1.4) 0.25
Seizure 1 (0.5) 3 (1.4) 0.62
Dyspnea 0 4 (1.9) 0.12
Chest pain 3 (1.5) 4 (1.9) 1.00
Anxiety 1 (0.5) 4 (1.9) 0.37
Depression 1 (0.5) 2 (1.0) 1.00
Diverticulitis 1 (0.5) 2 (1.0) 1.00
Inguinal hernia 1 (0.5) 2 (1.0) 1.00
Bariatric surgery 4 (2.0) 1 (0.5) 0.21
Viral infection 1 (0.5) 2 (1.0) 1.00
Allergic drug reaction 1 (0.5) 2 (1.0) 1.00
Traumatic injury 6 (2.9) 3 (1.4) 0.33
Vaginal childbirth¶ 2 (1.0) 3 (1.4) 1.00
* Not listed are primary composite end point events (see Table 2) and PFO clo-
sures in the medical-therapy group (see Fig. S3 in the Supplementary Appen-
dix). P values were obtained from a chi-square test (or Fisher’s exact test if the 
expected number of events was less than 5).
† Procedural complications included two episodes of minor bleeding at the access 
site and one periprocedural episode of atrial fibrillation that resolved within  
6 hours; all were classified as minor.
‡ All admissions and myocardial infarctions were classified as serious adverse 
events.
§ One atrial fibrillation was periprocedural and resolved within 6 hours. In the 
PFO-closure group, one patient had atrial ectopy, one had sick sinus syndrome, 
and one had atrioventricular block. In the medical-therapy group, one patient 
had atrial ectopy.
¶ Vaginal childbirth was subsumed under adverse events for the purpose of 
analysis.
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TIA within 2 years, death from any cause within 
30 days, and death from neurologic causes from 
31 days to 2 years. The estimated hazard ratio 
for the primary composite end point in the clo-
sure group versus the medical-therapy group was 
0.78 (95% CI, 0.45 to 1.35). In the RESPECT trial, 
the primary end point was recurrent is che mic 
stroke; the hazard ratio for closure versus medi-
cal therapy was 0.49 (95% CI, 0.22 to 1.11).23 
Thus, all three trials show a trend in favor of the 
closure group. However, the baseline risks, de-
vices used, and end-point definitions differed 
among the trials, making direct comparisons of 
event rates and treatment effects difficult.
In conclusion, our trial compared the closure 
of patent foramen ovale and the administration of 
medical therapy in patients with a patent foramen 
ovale and a history of cryptogenic embolism. We 
did not find a significant reduction in the risk of 
recurrent embolic events or death in the closure 
group, as compared with the medical-therapy 
group.
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